Search alternatives:
largest decrease » larger decrease (Expand Search), marked decrease (Expand Search)
teer decrease » greater decrease (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
largest decrease » larger decrease (Expand Search), marked decrease (Expand Search)
teer decrease » greater decrease (Expand Search)
we decrease » _ decrease (Expand Search), a decrease (Expand Search), nn decrease (Expand Search)
-
681
-
682
-
683
-
684
-
685
Flow chart of experimental protocol.
Published 2024“…SBP showed an increasing trend, but this was not statistically significant (<i>p</i> = 0.108). Interestingly, we observed significant decreases in arterial stiffness and PWV in POST_VM when comparing with PRE_VM (<i>p</i><0.001 and <i>p</i><0.001, respectively). …”
-
686
A representative ultrasound axis image.
Published 2024“…SBP showed an increasing trend, but this was not statistically significant (<i>p</i> = 0.108). Interestingly, we observed significant decreases in arterial stiffness and PWV in POST_VM when comparing with PRE_VM (<i>p</i><0.001 and <i>p</i><0.001, respectively). …”
-
687
-
688
-
689
-
690
-
691
-
692
Data from: <b>Selection and genetic variation in plasticity drive age-related decreases in among-individual behavioural correlations</b>
Published 2025“…Our findings indicate that the magnitudes of both the positive among-individual and genetic correlations were maintained across nymph and young adult stages, but significantly decreased with age during adulthood. This decrease was due to both selection and genetic variation in age-related behavioural plasticity. …”
-
693
-
694
-
695
Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”
-
696
Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”
-
697
Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf
Published 2025“…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…”
-
698
-
699
-
700